MaxCyte, Inc. Presentations at Cell & Gene Therapy Congress
October 23 2019 - 2:01AM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
23 October 2019
MaxCyte Announces Presentations at 5th Annual Cell & Gene
Therapy Congress Highlighting Unique Promise of Its Technology
Gaithersburg, Maryland - 23 October 2019 - MaxCyte (LSE: MXCT,
MXCS), the global cell-based therapies and life sciences company,
announces two presentations at the 5th Annual Cell & Gene
Therapy Congress (ACGTC) taking place 29-30 October in London, UK,
which showcase the Company's cell therapy technology.
Details of the presentations are as follows:
Presenter: Michael O'Dwyer, Founder and CSO, ONK Therapeutics
Title: The rationale for the development of CAR-NK cells for the
treatment of Multiple Myeloma
Date: Tuesday, 29 October, 9:30 a.m. - 10:00 a.m. GMT
Location: Bourgogne Conference Room
The presentation will focus on the background to treatment of
multiple myeloma with current unmet medical needs and experience to
date with CAR-T cells in myeloma. It will also include an
introduction to NK cells and their function in myeloma and the
rationale for development of CAR-NK in myeloma. Technology utilized
was licensed from MaxCyte.
Presenter: Chris Mann, Director, Field Applications Scientists Team, MaxCyte
Title: Aligning Gene Editing & Cell Line Engineering to
Improve Biotherapeutic Discovery, Efficacy and Bioproduction
Date: Wednesday, 30 October, 12:30 p.m. - 1:00 p.m. GMT
Location: Bourgogne Conference Room
The presentation will focus on lessons and engineering
approaches from cell therapy and how they can be harnessed to
rapidly generate custom CHO cell lines using gene editing,
including engineering of CHO manufacturing cell lines and
generation of CHO cell lines with integration landing pad for
simplified engineering. The presentation will also include a case
study entitled: "Improving HIV vaccine immunogenicity and
manufacturing using CRISPR-mediated creation of CHO MGAT- cell line
and rapid generation of stable gp120-expressing cell lines".
The conference takes place 29-30 October at Novotel London West
Hotel, London, United Kingdom. For more information, please visit:
https://www.oxfordglobal.co.uk/cell-series-uk/genetherapy/
Doug Doerfler, CEO of MaxCyte, said: "We are a life science
business committed to driving the next generation of cell-based
therapies, and our technology has become the go-to for
cell-engineering. The Company is experiencing exciting progress,
with new partnerships and expanded collaborations demonstrating an
increasing interest in MaxCyte among leading gene-editing and
immuno-oncology companies. We are very pleased to be presenting at
the ACGTC on the potential of our advanced therapy
technologies."
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, including with all of
the top ten global biopharmaceutical companies. The Company now has
more than 80 partnered programme licenses in cell therapy with more
than 45 licensed for clinical use, including six announced
commercial licenses with aggregate potential milestones of more
than $450m. With its robust delivery technology platform, MaxCyte
helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPGGBAUUPBUAW
(END) Dow Jones Newswires
October 23, 2019 02:01 ET (06:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024